Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jonmu Sun Sun, MD,PhD
CONTACT
Lead
Samsung Medical Center
Although lazertinib has been successfully established as a standard first-line targeted therapy for EGFR-mutant non-small cell lung cancer (NSCLC) in South Korea, its long-term clinical utility is frequently challenged by treatment limiting toxicities. Chief among these is peripheral neuropathy, which manifests as severe numbness, tingling sensations, or painful muscle cramps in the hands and feet. This distressing side effect not only profoundly impairs patients' daily functioning and overall quality of life but also frequently necessitates unplanned dose reductions or treatment interruptions, potentially compromising long-term oncological outcomes. To address this clinical unmet need, this phase 2, open-label, randomized clinical trial will evaluate 177 newly diagnosed patients to investigate optimization strategies aimed at mitigating nerve toxicity. The study is designed around the hypothesis that initiating treatment with a lower starting dose of lazertinib (160 mg/day) and introducing preemptive magnesium supplementation will significantly reduce the incidence of moderate-to-severe (Grade 2 or higher) peripheral neuropathy. Ultimately, the researchers aim to demonstrate that this novel intervention strategy can establish a highly tolerable safety profile, thereby preventing treatment interruptions and enhancing patient compliance, all while successfully maintaining the robust therapeutic efficacy of the core cancer treatment.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
